Understanding how disease-causing parasites maintain their cellular machinery could unlock new therapeutic approaches for three devastating tropical diseases that collectively afflict 1.5 billion people globally. The discovery centers on glycosomes, specialized organelles that trypanosomatid parasites use differently than human cells for essential metabolic processes. Research teams have identified how these parasites evolved a unique protein trafficking system by repurposing ancient cellular machinery. The PEX38 protein, originally derived from the GET pathway that helps insert proteins into cell membranes, has been evolutionarily remodeled to become essential for glycosome function in trypanosomatids. This protein serves as a critical component in maintaining the organelles that these parasites depend on for survival. The finding represents a significant advance in understanding the cellular biology of organisms responsible for African sleeping sickness, Chagas disease, and leishmaniasis. This evolutionary adaptation appears unique to these parasites, creating a molecular vulnerability absent in human cells. The research provides compelling evidence that targeting parasite-specific organelle maintenance could offer a new therapeutic strategy. Unlike broad-spectrum approaches that often harm host cells, drugs designed around these glycosome-specific pathways could selectively disrupt parasite function while leaving human cellular processes intact. However, translating this basic science discovery into clinical applications remains challenging, requiring extensive drug development and testing phases. The work exemplifies how evolutionary biology insights can illuminate novel therapeutic targets, particularly for neglected diseases where traditional drug discovery approaches have struggled to deliver effective treatments.